Glioblastoma research collaboration between Porsolt, Gliocure, and University Hospital of Angers.

Porsolt, GlioCure, and CHU d’Angers have joined forces in the “Glio Preclinical Solutions (GPS)” collaborative project to develop new and innovative models for the evaluation of first- and best-in class cancer therapies for glioblastoma.

“This is an exciting collaboration, where Porsolt’s expertise and capabilities can assist with developing valuable tools, including in-vitro glioblastoma organoid models and patient-derived in-vivo models, to evaluate and support GlioCure’s GlioVector™ technology and further innovative drugs” said Dr. Guillaume Froget, President and CEO of Porsolt. Dr. Tristan Rupp, Head of Oncology at Porsolt added “This is a unique opportunity for Porsolt to participate in the development of innovative solutions for glioblastoma patients in collaboration with the university hospital of Angers and the team of the Pr. Phillippe Menei”.

“We are delighted to participate in the GPS project, which demonstrates that Pays-de-la-Loire has a wealth of expertise and know-how in a medical field where competition is global from the outset and success can only be collective at our scale,” said Louis-Marie Bachelot, CEO of GlioCure. “The development of new therapies is a long process, particularly in the field of neuro-oncology where the very high heterogeneity of tumors and the need for drugs to cross the blood-brain barrier that protects the brain multiply the difficulties. Having robust predictive models is therefore a valuable asset in the selection of new drug candidates.” said Dr. Claire Lepinoux-Chambaud, Head of Research at GlioCure.

Glioblastomas are the most common and aggressive brain tumors with a median 5-year patient survival of less than 10%. Approximately 250,000 new cases are diagnosed worldwide each year, with almost as many deaths recorded each year. Unfortunately, there are no currently available therapies that can efficiently prolong the lives of patients, due to the complexity and heterogeneity of this disease.

This collaboration is endorsed by the interregional cluster Atlanpole Biotherapies and is partially supported by a grant from the Region Pays de la Loire through a “Collaborative R&D Project”

For the full Press Release: